Characterizing tumor-infiltrating group 1 innate lymphoid cells in PyMT breast tumors
Methods in Cell Biology · 2025
DOI: 10.1016/bs.mcb.2024.03.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Methods in Cell Biology, 2025. Verfasst von Douglas C Chung und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Toronto, Toronto, ON, Canada; Tumor immunotherapy program, Princess Margaret Cancer Centre, University Health…. Hauptthemen laut MEDLINE: Immunity, Innate, Lymphocytes, Tumor-Infiltrating, Breast Neoplasms, Mammary Neoplasms, Experimental. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Alberta Cancer Foundation, Arnie Charbonneau Cancer Institute, University of Calgary, Canadian Cancer Society.
Abstract (Originalsprache)
Breast cancer is the most common cancer in women and continues to have a significant impact in cancer-associated deaths worldwide. Investigating the complex roles of infiltrating immune subsets within the tumor microenvironment (TME) will enable a better understanding of disease progression and reveal novel therapeutic strategies for patients with breast cancer. The mammary-specific expression of polyomavirus middle T oncoprotein (MMTV-PyMT) was first established in 1992 by William Muller and is the most commonly used genetically engineered mouse model (GEMM) for breast cancer research. Innate lymphoid cells (ILCs) are composed of a diverse family of effector cells known to play important roles in defense against pathogens, tissue homeostasis, and tumor immunity. In mice, group 1 ILCs are composed of NK cells and ILC1s, which have been shown to have differential roles within the TME. Here, we provide a detailed methodology in characterizing tumor-infiltrating NK cells and ILC1s in MMTV-PyMT breast tumor model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, University of Toronto, Toronto, ON, Canada; Tumor immunotherapy program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
- Tumor immunotherapy program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
- Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, Unive…
Förderung
- Alberta Cancer Foundation
- Arnie Charbonneau Cancer Institute, University of Calgary
- Canadian Cancer Society
Zitieren
APA
Chung, D. C., Elford, A. R., & Jacquelot, N. (2025). Characterizing tumor-infiltrating group 1 innate lymphoid cells in PyMT breast tumors. Methods in Cell Biology. https://doi.org/10.1016/bs.mcb.2024.03.008
Vancouver
Chung DC, Elford AR, Jacquelot N. Characterizing tumor-infiltrating group 1 innate lymphoid cells in PyMT breast tumors. Methods in Cell Biology. 2025. doi:10.1016/bs.mcb.2024.03.008
BibTeX
@article{Chung2025,
author = {Chung, Douglas C and Elford, Alisha R and Jacquelot, Nicolas},
title = {Characterizing tumor-infiltrating group 1 innate lymphoid cells in PyMT breast tumors},
journal = {Methods in Cell Biology},
year = {2025},
doi = {10.1016/bs.mcb.2024.03.008}
}
EUVIMED